The U.S. House of Representatives’ Committee on Oversight and Accountability will hold a hearing on April 11, 2024 to investigate the U.S. Food and Drug Administration’s (FDA) response to several issues, including the infant formula crisis, food safety regulation, facility inspections, and other topics. FDA Commissioner Robert M. Califf, M.D. is being called to testify at the hearing.

The Oversight Committee points to several recent crises within FDA’s purview as the impetus for the investigations and hearing. According to Oversight Committee Chairman James Comer (R-Kentucky), the Committee has identified how dysfunction at FDA could be leading to the occurrence of preventable crises. The Committee intends to hold Commissioner Califf accountable for FDA’s actions to address ongoing crises, how the agency is conducting inspections to prevent nationwide crises in the future, and how FDA intends to ensure it is protecting American consumers. Subcommittee Chairwoman McClain has been at the forefront of the Oversight Committee’s efforts to bring transparency to the FDA.